GPCR structural biology
Receptor-focused structural and molecular analysis helps reveal actionable binding sites, conformational states and mechanisms.
GPCR DRUG DISCOVERY • COMPUTATION • STRUCTURE
Engineering the next generation of GPCR medicines.
AlphaMol integrates computational biology, artificial intelligence, structural biology, medicinal chemistry and pharmacology to accelerate the discovery of differentiated therapeutics for challenging GPCR targets.
Integrated GPCR discovery
From molecular insight to experimentally validated drug candidates.
OUR SCIENCE
A disciplined discovery engine for difficult GPCR targets.
We combine complementary technologies instead of treating computational design, structural biology and experimental pharmacology as separate steps.
AI & computational design
Computer-aided discovery supports molecular generation, virtual screening, optimization, simulation and property prediction.
Experimental validation
Biochemical, pharmacological and translational experiments close the design loop and prioritize stronger development candidates.
INTEGRATED DISCOVERY PLATFORM
One iterative workflow from molecular hypothesis to candidate design.
AlphaMol connects GPCR biology, computation, medicinal chemistry strategy and experimental testing so each cycle of data informs the next design decision. Using this approach, AlphaMol has advanced two first-in-class drug candidates to clinical trials within three years and secured global patents for them.
Mechanism-led designStart from receptor state, binding mechanism and disease-relevant biology.
Multi-parameter optimizationBalance potency, selectivity, drug-like properties and developability earlier in discovery.
Rapid design–make–test learningUse experimental feedback to continuously refine computational models and chemistry priorities.
THERAPEUTIC INNOVATION
Focused programs. Differentiated GPCR biology.
Our internal portfolio applies the same integrated discovery approach across therapeutically important GPCR opportunities.
IMMUNOLOGY
Inflammation & immune disease
Small-molecule programs aimed at GPCR pathways involved in inflammatory and immune-mediated disease biology.
Learn moreMETABOLIC DISEASE
Metabolism & obesity
Programs targeting emerging GPCR biology with the potential to create new therapeutic options in metabolic disease.
Learn moreDISCOVERY PORTFOLIO
Next high-value GPCR targets
A broader discovery portfolio applies AlphaMol technologies to challenging and underexplored receptor targets.
Learn morePARTNERING
Built to collaborate with pharmaceutical and biotechnology partners.
AlphaMol has already established extensive collaborations with a number of domestic and overseas leading pharmaceutical companies, and welcomes strategic conversations around pipeline programs, research collaborations and GPCR-focused discovery opportunities.
LATEST FROM ALPHAMOL